The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | ASCO 2023: highlights in non-small cell lung cancer
Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, gives an overview of influential lung cancer trials at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including overall survival findings from the Phase III ADAURA trial (NCT02511106), which assessed osimertinib in non-small cell lung cancer (NSCLC) in the adjuvant setting. Dr Sabari additionally highlights results from the ALINA trial (NCT03456076) of alectinib in NSCLC. This interview took place at ASCO 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
